Recent research suggests that women taking GLP-1 medications like Ozempic or Wegovy around the time of conception may not face the heightened risk of birth defects previously feared. However, experts emphasize that current guidelines advising discontinuation before pregnancy should still be followed, as definitive evidence remains limited.
Emerging Findings from a Large-Scale Analysis
A meta-analysis of nearly 37,000 pregnancies found no significant increase in birth defects or fetal complications among women who took GLP-1s until discovering they were pregnant, compared to those on other diabetes medications. In fact, women continuing GLP-1 treatment early in pregnancy experienced fewer adverse maternal outcomes like high blood pressure and gestational diabetes.
This is notable because over 30% of women enter pregnancy with obesity, a condition linked to higher risks during gestation. The study suggests that weight and blood sugar management via GLP-1s may contribute to improved pregnancy outcomes, but researchers stress that this is only an observed correlation, not confirmed proof.
Why This Matters: A Shift in Understanding
For years, doctors advised stopping GLP-1s at least two months before trying to conceive, due to animal studies raising concerns about birth defects. This new data doesn’t invalidate that advice, but it does challenge the previously held assumption that even brief exposure during early pregnancy is necessarily harmful.
The study’s observational nature means it cannot definitively prove safety; only larger, prospective trials can provide conclusive answers. However, the findings justify further investigation into the potential benefits of GLP-1s for women with obesity or diabetes who are planning to conceive.
Unintended Fertility Effects and Birth Control
Beyond pregnancy safety, GLP-1s can also increase fertility by restoring ovulation, particularly in women with insulin resistance or PCOS. This has led to reports of unexpected pregnancies (“Ozempic babies”), highlighting the need for reliable contraception while on these medications.
Experts recommend using backup methods, as birth control pills may be less effective when combined with GLP-1s. If accidental pregnancy occurs, discontinuing the drug and consulting an ob-gyn is advised.
The Bottom Line
While these findings are encouraging, current guidelines remain unchanged: stop GLP-1s before attempting conception. The research underscores the urgent need for more rigorous studies to determine the true safety profile of these drugs during pregnancy, but does not suggest any immediate change in clinical advice.
